Our Impact

See how ASCEND can revolutionize your research

130M+

Saving efficiency across all partners in 2022 alone

40%

Partner analysis revealed that preclinical programs could be accelerated by at least 40%

40%

Percentage of projects that identified a new indication to explore or an additional target gene not previously considered

33%

Percentage of projects that identified an early safety or efficacy risk to improve R&D productivity.

How we work with you

Learn more

Scientific

1:1 engagement with scientists and research leaders to accelerate success for must-win programs

Financial

Healthscan analysis of the portfolio to identify areas of preclinical pipeline with greatest opportunity for efficiency gain.

Technical

Partner with internal data science and IT to uncover opportunities to augment internal initiatives.

Enterprise Customers

If your company has an enterprise license, click your logo for login options:

Not an enterprise customer?

Without the platform, it would have taken me hours to find the antibody I needed, but with it, it took me a few minutes.

Industry scientist at top 20 pharma

The platform is really, really useful—we save a lot of time and energy, and it’s helpful to communicate between us.

Industry scientist at top 20 pharma

The quality of the data is the number one value-add. I can narrow the field down to 2 or 3 candidates, compared to 10 or 20

Industry scientist at top 20 pharma

It would have been absolutely impossible to find a commercially available antibody for our experiment without the platform

Industry scientist at top 20 pharma

Industry scientist at top 20 pharma
Industry scientist at top 20 pharma
Industry scientist at top 20 pharma
Industry scientist at top 20 pharma